Researchers are gathering ongoing information on the safety and performance of Medtronic products that are already available on the market. This registry study aims to support patients, hospitals, clinicians, regulators, payers, and the medical industry by simplifying the process of monitoring these products and providing up-to-date performance data.
The study involves collecting data on patients who have received or are planned to receive Medtronic medical devices or therapies. Enrollment includes both prospective and retrospective participants within a specific time frame related to their therapy start. There are no specific interventions assigned, as this is an observational registry.
Participants provide written consent and are followed periodically, typically every 6 to 12 months depending on the therapy, to assess the safety and effectiveness of their Medtronic product. Researchers collect information from medical records and follow-up visits to monitor outcomes over time. Participants may be followed for many years, with the study currently planned through January 2040.
CONDITIONS
Brief Title
Product Surveillance Registry
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
Patient has or is intended to receive or be treated with an eligible Medtronic product
Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment
You will not qualify if you...
Patient who is, or will be, inaccessible for follow-up
Patient with exclusion criteria required by local law
Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Up to several years depending on therapy
Participants who undergo routine care with eligible Medtronic products are observed for safety and effectiveness over time.
Visits every 6 to 12 months depending on therapy
Trial Site Locations
Total: 393 locations
1
Birmingham, Alabama, United States
Actively Recruiting
2
Huntsville, Alabama, United States
Actively Recruiting
3
Chandler, Arizona, United States
Actively Recruiting
4
Phoenix, Arizona, United States
Actively Recruiting
5
Little Rock, Arkansas, United States
Actively Recruiting
6
Aliso Viejo, California, United States
Actively Recruiting
7
Chula Vista, California, United States
Actively Recruiting
8
Colton, California, United States
Actively Recruiting
9
La Jolla, California, United States
Actively Recruiting
10
Los Angeles, California, United States
Actively Recruiting
11
Napa, California, United States
Actively Recruiting
12
Redwood City, California, United States
Actively Recruiting
13
Salinas, California, United States
Actively Recruiting
14
San Diego, California, United States
Actively Recruiting
15
Stanford, California, United States
Actively Recruiting
16
Torrance, California, United States
Actively Recruiting
17
Ventura, California, United States
Actively Recruiting
18
Aurora, Colorado, United States
Actively Recruiting
19
Colorado Springs, Colorado, United States
Actively Recruiting
20
Lakewood, Colorado, United States
Actively Recruiting
21
Darien, Connecticut, United States
Actively Recruiting
22
Hartford, Connecticut, United States
Actively Recruiting
23
New Haven, Connecticut, United States
Actively Recruiting
24
Washington D.C., District of Columbia, United States
Safety and efficacy of an intrinsic antitachycardia pacing algorithm in patients from Japan and South Korea: results from a cardiac device registry in the Asia Pacific region.